Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:5HB's EV-to-EBITDA is ranked worse than 51.37% of 401
companies
in the Biotechnology industry
Industry Median: 13.6
vs FRA:5HB: 15.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shanghai Haohai Biological Technology Co (FRA:5HB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Haohai Biological Technology Co's PE Ratio (TTM) for today is calculated as:
Shanghai Haohai Biological Technology Co's share price for today is €1.78.
Shanghai Haohai Biological Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co EV-to-EBITDA Chart
Shanghai Haohai Biological Technology Co Annual Data
FRA:5HB vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co EV-to-EBITDA vs Biotechnology Industry
Shanghai Haohai Biological Technology Co's current Enterprise Value is €591.9 Mil.
Shanghai Haohai Biological Technology Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €39.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a EV-to-EBITDA of 15.06 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Haohai Biological Technology Co. This is 99% above median its historical median of 7.57. Over the past decade, Shanghai Haohai Biological Technology Co's EV-to-EBITDA has ranged from 3.61 to 50.68. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #206 out of 401 companies in the Biotechnology industry, placing it in the top 51.4%.
Is Shanghai Haohai Biological Technology Co's EV-to-EBITDA too high?
Shanghai Haohai Biological Technology Co's current EV-to-EBITDA of 15.06 is 99% above median its 10-year median of 7.57. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 50.68. The Biotechnology industry median EV-to-EBITDA is 13.60. Shanghai Haohai Biological Technology Co's value of 15.06 is 10.7% above this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #206 out of 401 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #206 out of 401 companies for EV-to-EBITDA. This places Shanghai Haohai Biological Technology Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.60. Shanghai Haohai Biological Technology Co's value of 15.06 is 10.7% above this benchmark. Historically, Shanghai Haohai Biological Technology Co's own EV-to-EBITDA has ranged from 3.61 to 50.68 over the past decade. While the company's 10-year median is 7.57 vs. the industry median of 13.60, Shanghai Haohai Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.60, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current EV-to-EBITDA of 15.06 is 10.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Haohai Biological Technology Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current EV-to-EBITDA is 15.06, which is 99% above median its own 10-year median of 7.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a current EV-to-EBITDA of 15.06. The stock's GF Value™ is €2.84, compared to a current price of €1.78 — trading 37.3% below its estimated fair value. The current EV-to-EBITDA is 15.06, which is 99% above median its 10-year median of 7.57 and 10.7% above the Biotechnology industry median of 13.60. Shanghai Haohai Biological Technology Co's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current EV-to-EBITDA is 15.06 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.78 is trading 37.3% below its estimated GF Value™ of €2.84.
Key valuation signals for FRA:5HB:
EV-to-EBITDA: 15.06 (99% above median its 10-year median of 7.57)
GF Value™: €2.84 vs. price of €1.78 (37.3% below fair value)
Industry Position: 10.7% above the Biotechnology median (#206 of 401)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
86GF Score
Get the complete analysis for FRA:5HB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
